Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain …
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
[HTML][HTML] Effect of antiplatelet therapy on survival and organ support–free days in critically ill patients with COVID-19: a randomized clinical trial
Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …
Pbx4 is required to restrict second heart field and ventricular outflow tract size
K Linstrum - 2015 - rave.ohiolink.edu
Patterning of the vertebrate heart is a complex process, the failure of which can result in a
variety of cardiovascular defects. Congenital cardiac outflow tract (OFT) defects account for 20-…
variety of cardiovascular defects. Congenital cardiac outflow tract (OFT) defects account for 20-…
Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19.
IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is
uncertain. OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for …
uncertain. OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for …
Effect of P2Y12 inhibitors on survival free of organ support among non–critically ill hospitalized patients with COVID-19: a randomized clinical trial
…, R Wunderly, M Buxton, T Roberts, K Linstrum… - Jama, 2022 - jamanetwork.com
Importance Platelets represent a potential therapeutic target for improved clinical outcomes
in patients with COVID-19. Objective To evaluate the benefits and risks of adding a P2Y12 …
in patients with COVID-19. Objective To evaluate the benefits and risks of adding a P2Y12 …
[HTML][HTML] Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21 days
…, K Collins, A Wells, RD Bart, K Linstrum… - Contemporary Clinical …, 2022 - Elsevier
Outpatient treatments that limit progression to severe coronavirus disease 2019 (COVID-19)
are of vital importance to optimise patient outcomes and public health. Monoclonal …
are of vital importance to optimise patient outcomes and public health. Monoclonal …
Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial
…, P Kruger, F Lamontagne, PR Lawler, K Linstrum… - Jama, 2020 - jamanetwork.com
Importance Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19)
is limited. Objective To determine whether hydrocortisone improves outcome for …
is limited. Objective To determine whether hydrocortisone improves outcome for …
Pbx4 limits heart size and fosters arch artery formation by partitioning second heart field progenitors and restricting proliferation
A Holowiecki, K Linstrum, P Ravisankar… - …, 2020 - journals.biologists.com
Vertebrate heart development requires the integration of temporally distinct differentiating
progenitors. However, few signals are understood that restrict the size of the later-…
progenitors. However, few signals are understood that restrict the size of the later-…
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
